alphaveGLAXO₹2,858.00

Glaxosmithkline Pharmaceuticals Ltd.

Annual Quarterly₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹48,417 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	957.0	805.3	929.8	814.7	1,010.8	949.4	974.4	805.2	979.9	1,041.3	995.3	938.4
Other Income	28.2	28.1	29.8	35.6	34.5	35.1	40.7	43.7	33.6	32.1	36.0	43.8
Total Income	985.2	833.4	959.6	850.3	1,045.3	984.5	1,015.1	848.9	1,013.5	1,073.4	1,031.3	982.2
Expenses
+ Cost of Materials Consumed	91.2	91.0	204.6	138.2	149.0	97.5	115.2	128.1	115.1	79.9	113.1	73.0
+ Purchases of Stock-in-Trade	260.6	162.5	255.7	172.7	216.7	164.2	291.4	232.1	232.7	217.3	228.4	378.6
+ Changes in Inventories	2.6	63.4	-93.2	-15.7	18.8	97.5	-54.7	-72.4	7.7	66.7	2.5	-123.6
+ Employee Benefit Expense	145.2	141.4	172.8	151.3	150.7	124.7	153.0	152.6	138.1	151.9	164.8	159.0
+ Finance Costs	0.4	0.3	0.8	0.4	0.3	0.1	0.6	0.4	0.5	1.2	0.6	1.0
+ Depreciation & Amortisation	18.1	17.1	18.1	16.4	16.9	18.8	14.7	15.5	17.4	20.3	13.2	15.8
+ Other Expenses	167.9	129.0	132.6	137.6	153.9	173.6	136.3	113.7	150.6	154.2	135.6	156.0
Total Expenses	686.0	604.6	691.4	600.9	706.2	676.4	656.5	569.9	662.2	691.4	658.2	659.8
EBITDA	289.5	218.1	257.3	230.5	321.7	291.9	333.2	251.2	335.7	371.3	350.9	295.5
EBIT	271.4	201.0	239.2	214.1	304.9	273.1	318.5	235.7	318.3	351.0	337.8	279.7
Profit
PBT before Exceptional Items	299.2	228.7	268.2	249.4	339.1	308.1	358.6	279.0	351.4	382.0	373.1	322.5
+ Exceptional Items	0.0	-163.3	2.4	0.0	4.7	0.0	0.0	0.0	2.6	18.0	0.0	0.0
Pretax Income	299.2	65.4	270.6	249.4	343.8	308.1	358.6	279.0	354.0	399.9	373.1	322.5
+ Current Tax	91.3	31.4	61.7	63.6	98.8	73.5	90.2	74.0	96.1	102.3	88.3	82.0
+ Deferred Tax	-9.6	-11.7	14.5	3.5	-7.5	4.7	5.6	0.0	0.4	2.1	7.0	3.3
Tax Expense	81.7	19.7	76.1	67.1	91.3	78.2	95.7	74.0	96.5	104.3	95.2	85.3
Net Income	217.5	45.7	194.5	182.3	252.5	229.9	262.9	205.0	257.5	295.6	277.9	237.2
+ Net Income — Continuing Ops	217.5	45.7	194.5	182.3	252.5	229.9	262.9	205.0	257.5	295.6	277.9	237.2
+ Other Comprehensive Income	0.0	-3.5	-0.7	0.0	0.0	1.2	-3.8	0.0	0.0	6.2	-13.7	0.0
Total Comprehensive Income	217.5	42.2	193.8	182.3	252.5	231.1	259.0	205.0	257.5	301.8	264.1	237.2
Net Income to Common	217.5	45.7	194.5	0.0	—	—	0.0	0.0	0.0	0.0	—	—
Per Share
Basic EPS	12.84	9.89	11.48	10.76	14.67	13.57	15.52	12.10	15.07	16.54	16.40	14.00
Diluted EPS	12.84	2.70	11.48	10.76	14.91	13.57	15.52	12.10	15.20	17.45	16.40	14.00
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-3.8	—	0.0	6.2	-13.7	—
+ Items NOT to be Reclassified to P&L	—	-4.7	-0.9	—	—	1.6	-5.1	—	—	8.3	-18.3	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-1.3	—	0.0	2.1	-4.5	—
+ Tax on Items NOT to be Reclassified — alt tag	—	-1.2	-0.2	—	0.0	0.4	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	217.5	42.2	-0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	12.84	9.89	11.48	10.76	14.67	13.57	15.52	12.10	15.07	16.54	16.40	14.00
Diluted EPS — Continuing Operations	12.84	2.70	11.48	10.76	14.91	13.57	15.52	12.10	15.20	17.45	16.40	14.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	602.6	488.4	562.7	519.4	626.3	590.3	622.4	517.5	624.4	677.4	651.3	610.5
Gross Margin %	62.96	60.65	60.52	63.75	61.96	62.17	63.88	64.27	63.72	65.06	65.44	65.05
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	299.2	228.7	268.2	249.4	339.1	308.1	358.6	279.0	351.4	382.0	373.1	322.5
− Exceptional Items (reconciliation)	0.0	-163.3	2.4	0.0	4.7	0.0	0.0	0.0	2.6	18.0	0.0	0.0
Net Income Adj (tax-effected)	217.5	159.8	192.8	182.3	249.1	229.9	262.9	205.0	255.6	282.3	277.9	237.2
EPS Adj	12.84	34.57	11.38	10.76	14.47	13.57	15.52	12.10	14.96	15.80	16.40	14.00
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4	169.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.